Anti-HIV dual specificity antibodies and methods of HIV treatment

Patent metadata

Field	Value
Publication number	US-9988438-B2
Application number	US-201414907360-A
Country	US
Kind code	B2
Filing date	Jul 23, 2014
Priority date	Jul 25, 2013
Publication date	Jun 5, 2018
Grant date	Jun 5, 2018

Abstract

Dual variable domain immunoglobulins (DVD Igs) are provided capable of tetravalent binding to bispecific sites of the human immunodeficiency virus (HIV). The DVD Igs may be asymmetric and may have more variable domains on either the light chain or the heavy chain of the Igs. The DVD Igs may have specificity for gp41 and gp120. Therapies are provided using DVD Igs to neutralize HIV viral loads.

First claim

What is claimed is:

1. An asymmetric double variable domain (DVD) antibody comprising at least one immunoglobulin heavy chain-light chain cross-linked pair, wherein each immunoglobulin heavy chain-light chain pair comprises:
a first variable domain having binding affinity for an epitope of an HIV gp41 polypeptide and consisting of an immunoglobulin heavy chain variable (V H ) region and an immunoglobulin light chain variable (V L ) region; and
a second variable domain having binding affinity for an epitope of an HIV gp120 polypeptide,
wherein said second variable domain is attached by a linker peptide to either the immunoglobulin V H region or the immunoglobulin V L region of the first domain, but is not attached to both the immunoglobulin V H region and the immunoglobulin V L region of the first variable domain.

2. The asymmetric DVD-antibody of claim 1 , wherein the second variable domain having binding affinity for an epitope of an HIV gp120 polypeptide is a CD4 polypeptide or a fragment thereof.

3. The asymmetric DVD-antibody of claim 1 , wherein the first variable domain having binding affinity for an epitope of an HIV gp41 polypeptide is the immunoglobulin variable region of monoclonal antibody 7B2.

4. The asymmetric DVD-antibody of claim 1 , wherein the V H region of the first variable domain has the second variable domain attached thereto by the linker peptide and the the V L region of the first variable domain does not have the second variable domain attached thereto.

5. The asymmetric DVD-antibody of claim 1 , wherein the V L region of the first variable domain has the second variable domain attached thereto by the linker peptide, and the the V H region of the first variable domain does not have the second variable domain attached thereto.

6. The asymmetric DVD-antibody of claim 1 , wherein the linker peptide comprises a helical core.

7. The asymmetric DVD-antibody of claim 1 , wherein the linker peptide comprises a helical core having a flexible domain at both the N-terminus and the C-terminus thereof.

8. The asymmetric DVD-antibody of claim 1 , wherein the heavy chain has an amino acid sequence selected from the group consisting of: SEQ ID Nos.: 3, 4, and 8, and wherein the light chain has an amino acid sequence selected from the group consisting of: SEQ ID Nos.: 5, 6, and 7.

9. The asymmetric DVD-antibody of claim 1 , wherein the cross-linked heavy and light chain pairs are paired amino acid sequences-selected from the group consisting of: SEQ ID Nos.: 3 and 5, 4 and 6, 8 and 5, 3 and 7, 8 and 6, and 4 and 7.

10. The asymmetric DVD-antibody of claim 9 , wherein the cross-linked heavy and light chain pairs are paired amino acid sequences selected from the group consisting of: SEQ ID Nos.: 8 and 5, 3 and 7, 8 and 6, and 4 and 7.

11. The asymmetric DVD-antibody of claim 1 , wherein the linker peptide has an amino acid sequence according to SEQ ID NO: 9.

12. The asymmetric DVD-antibody of claim 1 , wherein the linker peptide has an amino acid sequence according to SEQ ID NO: 10.

13. The asymmetric DVD-antibody of claim 1 , wherein the asymmetric immunoglobulin is admixed with a pharmaceutically acceptable carrier.

14. The asymmetric DVD-antibody of claim 1 , wherein each of the heavy and the light chains is an expression product from an expression vector.

15. The asymmetric DVD-antibody of claim 14 , wherein at least one of the heavy and the light chain expression products from the expression vector has an N-terminal leader sequence attached thereto.

16. A method of reducing the infectivity of an HIV by contacting said virus with an asymmetric DVD-antibody comprising at least one immunoglobulin heavy chain-light chain cross-linked pair, wherein each immunoglobulin heavy chain-light chain pair comprises:
a first variable domain having binding affinity for an epitope of an HIV gp41 polypeptide and consisting of an immunoglobulin heavy chain variable (V H ) region and an immunoglobulin light chain variable (V L ) region; and
a second variable domain having binding affinity for an epitope of an HIV gp120 polypeptide,
wherein said second variable domain is attached by a linker peptide to either the immunoglobulin V H region or the immunoglobulin V L region of the first domain, but is not attached to both the immunoglobulin V H region and the immunoglobulin V L region of the first variable domain.

17. A method of reducing the viability of an HIV-infected cell by the steps of:
binding an asymmetric DVD-antibody to a cell infected with a strain of HIV, wherein the asymmetric DVD-antibody comprises at least one immunoglobulin heavy chain-light chain cross-linked pair, wherein each immunoglobulin heavy chain-light chain pair comprises:
a first variable domain having binding affinity for an epitope of an HIV gp41 polypeptide and consisting of an immunoglobulin heavy chain variable (V H ) region and an immunoglobulin light chain variable (V L ) region; and
a second variable domain having binding affinity for an epitope of an HIV gp120 polypeptide,
wherein said second variable domain is attached by a linker peptide to either the immunoglobulin V H region or the immunoglobulin V L region of the first domain, but is not attached to both the immunoglobulin V H region and the immunoglobulin V L region of the first variable domain, whereby said DVD-antibody binds to a cell surface polypeptide of the infected cell forming a cell-DVD-antibody complex; and
delivering a cytotoxic agent to the HIV-infected cell and reducing the viability of the HIV-infected cell by contacting said cell-DVD-antibody complex with a cytoxic agent capable of specifically recognizing the cell-bound DVD-antibody.

18. The method of claim 17 , wherein the cytotoxic agent is an engineered anti-immunoglobulin IgG antibody conjugated to a cytotoxic polypeptide, wherein the engineered anti-immunoglobulin IgG antibody specifically binds to a constant region of the asymmetric DVD-antibody.

19. The method of claim 18 , wherein the cytotoxic polypeptide is a ricin A chain.

Assignees

• Univ Louisiana State
• Board Of Supervisor Of Louisiana State Univ And Agricultural And Mechanical College

Inventors

• Pincus Seth
• Craig Ryan

Classifications

• A61P31/18

  for HIV · CPC title

• C07K2317/31

  multispecific · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• A61K38/1774

  Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules) · CPC title

• C07K2317/70

  characterized by effect upon binding to a cell or to an antigen · CPC title